Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses

Immunology

Volumn 106, Issue 1, 2002, Pages 113-121

  BenMohamed, Lbachir ^a   Krishnan, Radhika ^a   Auge, Catherine ^a   Primus, James F ^b   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; EPITOPE; HLA ANTIGEN; LIPOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MATRIX PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HELPER CELL; HUMAN; HUMAN CYTOMEGALOVIRUS; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0036241804     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01396.x     Document Type: Article

References (50)

1. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein
2. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans
3. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
4. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and CTL responses against a malaria liver stage antigen in mice and chimpanzees
5. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules
6. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
7. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
8. Extension of HLA-A*0201-restricted minimal epitope by N epsilon-palmitoyllysine increases the life span of functional presentation to cytotoxic T cells
9. IFN-gamma-derived lipopeptides: Influence of lipid modification on the conformation and the ability to induce MHC class II expression on murine and human cells
10. Mucosal immunity to infection with implications for vaccine development
11. Bacterial toxins as mucosal adjuvants
12. Lipid matrix-based vaccines for mucosal and systemic immunization
13. Antigen delivery systems: Nonliving micro-particles, liposomes, cochleates and ISCOMs
14. Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG micro-particles
15. Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations
16. Proteosome-lipopeptide vaccines: Enhancement of immunogenicity for malaria CS peptides
17. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes
18. Liposomes as carriers of peptide antigens: Induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides
19. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
20. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine
21. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses
22. Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens
23. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans
24. Optimism over vaccines administered via mucosal surfaces
25. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
26. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT (R192G)
27. Peripheral deletion of antigen-reactive T cells in oral tolerance
28. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity
29. Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)
30. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant
31. H response
32. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
33. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells
34. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses
35. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
36. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes
37. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants
38. Comparison of the role of complement in immunity to Schistosoma mansoni in rats and mice
39. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
40. New strategies for using mucosal vaccination to achieve more effective immunization
41. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins
42. LT (R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp
43. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide
44. Protection against measles virus-induced encephalitis by antibodies from mice immunized intranasally with a synthetic peptide immunogen
45. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo
46. Histopathological studies on the local reactions induced by complete Freund's adjuvant (CFA), bacterial lipopolysaccharide (LPS), and synthetic lipopeptide (P3C) conjugates
47. Immunostimulation by bacterial components. I. Activation of macrophages and enhancement of genetic immunization by the lipopeptide P3CSK4
48. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types
49. Lipopeptide particles as the immunologically active component of CTL inducing vaccines
50. Synthetic lipopeptides as novel adjuvants